MedTrace Logo

Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.

NCT07301658 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-12-24

No results posted yet for this study

Summary

A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision. The product was applied twice daily, and efficacy was assessed through dermatological scoring, instrumental measurements, and subjective questionnaires. Results aimed to show improvements in barrier function, hydration, skin texture, and reduction of erythema, dryness, and pruritus, with feedback on comfort and quality of life.

Conditions

  • Atopic Dermatitis (AD)

Interventions

OTHER

Novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.

Apply twice a day on the affected skin area to protect it, previously cleaned and dried. No rinsing is required. Volunteers were instructed not to use any other cosmetic product in the study area until the end of the study.

Sponsors & Collaborators

  • Centro Médico Complutense Grupo Virtus

    collaborator OTHER

  • i+Med S.Coop.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2023-06-06
Completion
2024-08-07

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07301658 on ClinicalTrials.gov